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Abstract
Background: We have previously used the ATAD5-luciferase high-throughput screening assay to identify genotoxic
compounds with potential chemotherapeutic capabilities. The successful identification of known genotoxic agents,
including the histone deacetylase inhibitor (HDACi) trichostatin A (TSA), confirmed the specificity of the screen since TSA
has been widely studied for its ability to cause apoptosis in cancer cells. Because many cancers have acquired mutations in
DNA damage checkpoints or repair pathways, we hypothesized that these cancers may be susceptible to treatments that
target compensatory pathways. Here, we used a panel of isogenic chicken DT40 B lymphocyte mutant and human cell lines
to investigate the ability of TSA to define selective pathways that promote HDACi toxicity.
Results: HDACi induced a DNA damage response and reduced viability in all repair deficient DT40 mutants although ATM-
nulls were least affected. The most dramatic sensitivity was observed in mutants lacking the homology dependent repair
(HDR) factor BLM or the non-homologous end-joining (NHEJ) and HDR factors, KU/RAD54, suggesting an involvement of
either HDR or NHEJ in HDACi-induced cell death. To extend these findings, we measured the frequencies of HDR and NHEJ
after HDACi treatment and monitored viability in human cell lines comparably deficient in HDR or NHEJ. Although no
difference in HDR frequency was observed between HDACi treated and untreated cells, HDR-defective human cell lines
were clearly more sensitive than wild type. Unexpectedly, cells treated with HDACis showed a significantly elevated NHEJ
frequency.
Conclusions: HDACi targeting drugs induced significant increases in NHEJ activity in human cell lines but did not alter HDR
frequency. Moreover, HDR is required for cellular resistance to HDACi therapy; therefore, NHEJ does not appear to be a
critical axis for HDACi resistance. Rather, HDACi compounds induced DNA damage, most likely double strand breaks (DSBs),
and HDR proficiency is correlated with cell survival.
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Introduction
DNA double strand breaks (DSBs) are toxic lesions that
represent a major threat to cell survival. Homologous recombi-
nation (HR), also known as homology dependent repair (HDR)
and non-homologous end joining (NHEJ) are two major pathways
that repair DNA DSBs [1,2,3]. The HDR pathway, which is
largely considered an error free process, functions mainly in the S
and G2 phases of the cell cycle when a sister chromatid is available
for use as a template [4]. In eukaryotes, the RAD51 strand
exchange protein is a central player in HDR and mediates the
process of synapse from a wild type allele {for review see [2]}.
Other HDR proteins generally function as positive or negative
regulators of RAD51. Positive regulators include BRCA1 and
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BRCA2. BRCA1 binds directly to the DSB, participates in the
processing of the DSB by promoting 59-end resection, and is
required for the recruitment of RAD51 [4]. BRCA2 promotes
RAD51-mediated strand exchange, thus controlling the assembly
of the nucleofilament required for synapse [4]. Negative regulators
of HDR such as BLM and FANCM have evolved to prevent
uncontrolled or unscheduled HDR [5], which could ultimately
lead to genomic DNA rearrangements [2]. BLM [2], RecQ5 [6],
and FANCJ [7] helicases were reported to destabilize RAD51-
coated single-stranded DNA (ssDNA) and FANCM is a translocase
that disrupts intermediate RAD51-coated D-loops [2]. Recently,
PARI [8] and RTEL [9] have been suggested as putative
homologs to the yeast anti-recombination protein, Srs2. Given
the importance of HDR in genome stability, it is not surprising
that many of the proteins involved in HDR have been found to
increase cancer susceptibility when mutated. Mutations in BRCA2
and/or BRCA1 increase predisposition to breast and ovarian
cancers [4], while mutations in BLM or FANCM are associated
with syndromes showing elevated genomic instability and cancer
susceptibility in general [2,10].
NHEJ is an error-prone pathway whereby the two broken ends
of the DSB are conjoined by direct ligation without regard to
sequence homology, but generally involve microhomology of a few
bases. Whereas HDR is the major repair mechanism in the S and
G2 phases of the cell cycle, the NHEJ pathway is primarily active
in G1 in part because the repair protein 53BP1 binds to the
broken ends and prevents resection, thereby repressing an early
key step in HDR [3]. During NHEJ, the KU70-KU80 heterodi-
mer (Ku) holds the broken ends in direct proximity and recruits
other NHEJ proteins including the DNA-dependent protein kinase
catalytic subunit (DNA-PKcs), Artemis, and DNA Ligase IV
(LIGIV). DNA-PKcs, Ku and the DNA at the site of the DSB
together form an active kinase complex (DNA-PK). Ku, Artemis,
XRCC4 and LIGIV are all targets of DNA-PK, although
phosphorylation of these proteins is, surprisingly, dispensable for
NHEJ in vivo [11,12,13]. In contrast, autophosphorylation of
DNA-PKcs is required for proper NHEJ [14]. Artemis and Ku
participate in the processing of the DSB, and then the
heterodimeric complex of XRCC4 and LIGIV ligate the broken
DNA ends [15]. As with HDR, inappropriate NHEJ is detrimental
to the cell and results in chromosomal deletions, insertions or
translocations, especially when more than one DSB is available for
repair [16]. Because Ku spatially stabilizes DSB ends, its loss can
also lead to inappropriate joining outcomes [16]. Mutations in
ARTEMIS are associated with severe combined immunodeficiency
and predisposition to lymphomas [16]. Germ-line mutations in
LIGIV result in LIG4 syndrome and predispose individuals to
lymphoid malignancies [16]. Lastly, mutations of DNA-PKcs cause
severe combined immunodeficiency in mice [17,18,19,20]. In
animals, NHEJ appears to be the major pathway for DSB repair
while HDR, a high fidelity process, is much more limited. Recent
evidence has suggested that the DNA synthesis associated with
HDR can also reprogram DNA methylation signatures in the
repaired segment, thereby leading to silencing of tumor suppressor
genes or activation of oncogenes in daughter cells [21,22,23].
We recently developed a robust ATAD5-luciferase high-
throughput screening (HTS) assay based on the stabilization of
the DNA damage response protein ATAD5 to identify genotoxic
compounds and potential chemotherapeutic agents that act by
inducing DNA damage [24,25]. The ATAD5-luciferase HTS is a
tractable cell based screen that identified histone deacetylase
inhibitors (HDACis) as potent DNA damaging agents [25]. There
is significant general interest in epigenetic therapeutics and these
agents are currently under intense investigation for potential use as
anti-cancer drugs [26]. HDACi therapeutics increase histone
acetylation levels by inhibiting deacetylation of histones thus
modifying the chromatin structure and regulating gene expression
[27]. HDACis are highly pleiotropic and have numerous non-
histone targets including p53, NF-kB and Rb/E2F showing
widespread effects [26]. In the case of p53, this tumor suppressor
protein is stabilized and transcriptionally activated by hyperace-
tylation, which in turn activates DNA repair or pro-apoptotic
proteins [28]. Induction of cell cycle arrest, apoptosis and
differentiation, coupled with inhibition of metastasis and angio-
genesis, all combine to give HDACis a diverse set of anti-cancer
abilities [27,28]. TSA has been widely studied and shown to
increase apoptosis in a variety of cancer types. TSA also increases
the effectiveness of platinum-based therapies in human bladder
cancer cells [29]. Another HDACi suberoylanilide hydroxamic
acid (SAHA), has been extensively researched and was approved
by the FDA in 2006 for use in the treatment of cutaneous T cell
lymphoma [28]. Currently HDACis are being chemically modi-
fied to form new compounds combining the properties of the
HDACis and other anti-cancer agents [27].
Because DNA repair pathways are well conserved evolutionarily
we employed a panel of isogenic chicken DT40 B lymphocyte cell
lines to investigate whether HDACis specifically kill DNA repair-
deficient cells. Ease of target integration, a short doubling time and
an unusually long S phase are all characteristics that make DT40
cells ideal for studying DNA repair and genotoxicity [30]. Here,
we further examine the role that DNA repair pathways play in
HDR, a pivotal pathway in defining resistance to HDACi;
however, two different HDACi drugs strongly stimulate the
process of NHEJ. Thus, elevation of an error prone pathway
may aid in cytotoxicity of HDACi in cancer.
Results and Discussion
Previously we developed a high-throughput screen that used
ATAD5 as a biomarker to detect genotoxic compounds, and
described a preliminary screen of small chemical libraries [25]. In
this screen, we found that HDACis, including TSA, increased the
protein level of ATAD5 {Figure 1a and [25]} and activated DNA
damage responses (Figure 1b). In addition to an increased level of
cH2AX protein, pulsed-field gel electrophoresis (PFGE) confirmed
a slight increase in DNA DSBs after treatment with TSA indicated
by shorter DNA fragments. Many transformed cells are defective
in repairing certain types of DNA damage due to deficiencies in
DNA repair pathways. Transformed cells are usually highly
susceptible to HDACi drugs such as TSA or SAHA [31] which
also induce DNA damage (Figure 1b); thus, we reasoned that DNA
repair pathways such as HDR and NHEJ are likely important in
defining drug sensitivity in tumors. To test this, a panel of isogenic
chicken DT40 B lymphocyte cell lines, each of which is defective
in a different DNA repair pathway (Table 1), was screened for
viability after treatment with increasing concentrations of TSA.
The viability of the DT40 cells was assessed 48 hr after treatment,
using the CellTiter-Glo luminescent cell viability assay to detect
ATPase activity. Compared to wild-type, all mutant DT40 cell
lines tested displayed some degree of sensitivity to TSA (Figure 2a
and Table 2). ATM-deficient cells were not as strongly affected as
other nulls but were still sensitized to TSA (Figure 2a and Table 2).
To determine if the effect was specific to TSA, we also measured
the viability of DT40 cell lines treated with increasing concentra-
tions of another HDACi, SAHA (Figure 2b). The toxicity profiles
of cells treated with either TSA or SAHA fell into three groups.
XPA-, SHPRH-, BLM-, and KU70/RAD54-null cells fell into the
first group of cells sensitive to both TSA and SAHA. POLb-,
Targeting of HDR by HDACi
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REV3-, FEN1-, UBC13- and FANCC-null cells fell into the second
group and only exhibited sensitivity to TSA. Finally, ATM-null
cells were in a group by themselves and exhibited sensitivity similar
to wild-type in the presence of both TSA and SAHA (Figure 2a
and b and Table 2). It appeared that DNA damage caused by TSA
requires all of the DNA repair pathways with the possible
exception of the ATM-dependent DNA damage response, which
is not thought to be required in HDR in normal mouse cells [32].
Also, base excision repair, the fanconi anemia pathway, and
translesion synthesis polymerases appeared to be dispensable for
the repair of SAHA-induced DNA damage.
KU70/RAD54- and BLM-null DT40 cells were the most
sensitive to both TSA and SAHA treatment compared to the
other mutant cell lines. KU70/RAD54-null cells are NHEJ and
HDR defective (NHEJ, due to the absence of KU70 and HDR due
to the loss of RAD54) [2,3]. In contrast, BLM-null cells exhibit a
hyper-recombination phenotype [33]. To test the possibility that
HDACi treatment causes promiscuous HDR, we measured the
frequency of sister chromatid exchange (SCE) in human retinal
pigment epithelial (RPE) cells after TSA treatment. The frequency
of SCE events for both treated and control-treated cells was not
significantly different (Figures 3a and b). We also performed a
single DSB-induced HDR assay using DR-GFP as a reporter in
human U2OS cells [34] and found that there was no difference in
HDR frequency between TSA-treated and control-treated cells
(Figures 3c and d). A similar and complementary approach was
performed using a HeLa cell line (iHO4.5GFP) containing twin
DR-GFP reporter cassettes [35] that undergo HDR following I-
SceI-induced DSB formation in the 59 cassette [23]. In
iHO4.5GFP cells, the I-SceI gene is under the control of the tet-
on promoter which activates upon exposure to doxycycline
(Figure 3e). Using this assay, we found that there was no
significant difference in the HDR frequency of TSA or SAHA-
treated cells compared to control-treated cells (Figures 3f and
Figure S1a). It is possible that the decrease in HDR frequency and
clear toxicity observed at higher doses of TSA (data not shown)
resulted from a suppression of HDR [36,37]. Taken together,
these data indicate that treatment with TSA or SAHA does not
increase the frequency of HDR. Indirect evidence that HDACi
drugs do not induce promiscuous HDR repair comes from
iHO4.5GFP uninduced (minus Dox) cells treated with TSA. If
TSA or SAHA directly or indirectly caused genome wide DNA
damage and HDR in the DR-GFP reporter, we would expect to
see an increase in the percent GFP readout in the absence of I-
SceI as some DNA damage and HDR should be randomly
directed to the DR-GFP locus. As shown in Figure 3f and Figure
S1a, there was no obvious increase in the percentage of GFP
positive cells in uninduced iHO4.5GFP cells treated with HDACi
alone.
The protein 53BP1 is recruited to DSBs and inhibits the 59 to 39
single-strand resection that initiates HDR [38]. ATM and
DNAPKcs, which are both required for NHEJ, phosphorylate
Figure 1. Trichostatin A induces DNA damage. (A) HEK293T ELG1-LUC cells were treated with 0.75 mM TSA or 50 mM SAHA for 48 hr. LUC
activity was measured using One-Glo. The graph represents average LUC activity 6 SD. Significance was calculated using a two-tailed t-test. (B)
HEK293T cells were treated with 50 mM TSA for 24 hr. Using the indicated antibodies proteins levels were visualized by Western blot analysis from
either the chromatin-bound fraction or total cell lysate. (C) HEK293T cells were treated with 100 uM TSA for 24 hours and then Pulsed-field gel
electrophoresis was performed.
doi:10.1371/journal.pone.0087203.g001
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53BP1 and p-53BP1 is a good marker for NHEJ initiation and
suppression of HDR. Human RPE cells were treated with TSA,
SAHA, DMSO as a negative control or hydroxyurea (HU) as a
positive control and the formation of p-53BP1 foci was monitored
by fluorescence microscopy. After a 1-hr treatment, there was no
difference in the number of p-53BP1 foci per cell in cells treated
with TSA, SAHA or DMSO (Figures 4a and b). Even after a 24-hr
treatment, we did not observe any difference in p-53BP1 foci in
TSA- or SAHA-treated cells compared to DMSO (data not
shown). In contrast, the majority of HU-treated cells had more
than 20 p-53BP1 foci (Figures 4a and b). We also used a HeLa cell-
based assay to measure the frequency of NHEJ with a dedicated
GFP reporter that cannot repair I-SceI DSBs by HDR (Figure 4c).
IHN20.22 cells contain a single copy of a GFP cassette under the
control of a CMV promoter that has been disrupted by an internal
adenoviral exon. Flanking the adenoviral exon are twin I-SceI sites
placed in an inverted orientation. Digestion with I-SceI results in
incompatible ends that must be repaired by NHEJ [39]. These
cells also have one stable copy of a cassette that encodes for
doxycycline-induced I-SceI expression. Using this assay we found
NHEJ to be significantly increased in cells treated with higher
concentrations of TSA or SAHA compared to non-treated cells
(Figures 4d and e and Figure S2a). We performed an additional
NHEJ assay using the U2OS cell line EJ2-GFP [40]. Unlike the
previous NHEJ assay, digestion with I-SceI in this cell line
generates compatible ends that are repaired by NHEJ. Using this
assay, we found that treatment with 100 nM TSA increased NHEJ
frequency although not at a statistically significant level (Figure
S2b). Reduction of 53BP1 by siRNA did not increase end joining
of compatible ends (Figure S2c and d). Finally, we note that SAHA
treated IHN20.22 cells in the absence of I-SceI cleavages (no Dox
treatment) display rather large increases in NHEJ frequency as
determined by increases in the percentage of GFP positive cells
(Figure S2e). From this result we infer that HDACi induced DNA
damage involves the generation of DSBs that are sensed and acted
upon by the NHEJ pathway. Based on independent and
complementary approaches, we conclude that HDACi treatment
increased the frequency of NHEJ at the DSB sites; however, we
did not observe enhanced 53BP1 recruitment to chromatin as
noted (Figures 4a and b). The recruitment of p-53BP1 into sites of
DNA damage, in particular at DSBs, involves histone H4
acetylation [41] and others have shown that HDACi treatment
can suppress 53PB1 focus formation [42].
Differences between avian and human cells could account for
our inability to detect an increase in HDR frequency; therefore,
we analyzed viability profiles in mammalian cell models.
Logistically, this is difficult since many of the comparable human
cell lines are not available. Nonetheless, to determine if human
cells defective in NHEJ were sensitive to HDACi, we knocked
down KU80 expression in HeLa cells with siRNA, and then
treated the cells with increasing concentrations of TSA, SAHA or,
as a positive control, MMS for 48 hr. Whereas KU86-knockdown
cells exhibited a reduced viability after treatment with MMS
compared to control knockdown cells (p = 0.03 for EC50s), there
was no difference in viability between control and KU80-
knockdown cells after treatment with TSA or SAHA even though
we achieved an almost complete reduction in KU80 protein level
(Figure 5a and Figure S1d). In addition, we treated LIG4-null
HCT116 cells, which are severely defective in NHEJ [43,44], with
increasing concentrations of TSA, SAHA or MMS and monitored
viability. LIG4-null cells are sensitive to a wide range of DNA
damaging agents [44] and they were therefore slightly more
sensitive to MMS treatment compared to wild type although not at
a statistically significant level (Figure 5b). However, we did not
observe any reduction in viability of LIG4-null cells compared to
HCT116 after treatment with either TSA or SAHA (Figure 5b).
TSA can therefore enhance NHEJ frequency at DSBs, but NHEJ
is dispensable for cell survival after TSA-induced DNA damage.
Likewise, HCC1937 cells, which lack a functional BRCA1 gene
and are therefore defective in HDR [45], were treated with TSA,
SAHA or MMS and viability was assessed after 48 hr. Compared
to the control cells that were complemented by BRCA1 cDNA
expression (wild-type), BRCA1 deficient HCC1937 cells exhibited
sensitivity to TSA and SAHA that was similar to that of MMS
(Figure 6a). To determine if HDR is indeed necessary to repair
HDACi induced damage, we knocked down RAD51 expression
Figure 2. Viability of isogenic chicken DT40 B lymphocyte cell lines following 48 hr treatment with (A) 0 to 0.04 mM TSA and (B) 0 to
3.125 mM SAHA. Viability was determined using CellTiter-Glo. The data represent the average of 3 independent experiments 6 SD.
doi:10.1371/journal.pone.0087203.g002
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with siRNA in HeLa cells and then treated with increasing
concentrations of TSA, SAHA or MMS and measured viability
after 24 hours. Compared to the control knockdown cells, cells
with a reduced expression of RAD51 were more sensitive to both
TSA and SAHA (Figure 6b and Figure S1e). RAD51 protein levels
were only reduced by one-third, compared to control knockdown
cells, which may have resulted in a decreased sensitivity to TSA
and SAHA. Although we did not observe the large reduction in
viability that was seen in DT40 cells, the sensitivity of BRCA1-
deficient cells and RAD51 deficient cells to HDACi and MMS is
mutually consistent with the notion that HDR is required to repair
HDACi-induced damage.
Because the results of our experiments with KU70/RAD54-null
avian cells were also slightly different from what we observed using
mammalian cell lines, we repeated viability assays using mamma-
lian cell lines lacking XPA, BLM, SHPRH, or FANCM [46]. We
chose to test these cell lines because the XPA-, BLM- SHPRH- and
FANCC-null avian cells were some of the most sensitive to either
TSA, SAHA or both. After a 48-hr treatment, XPA- and BLM-
mutant human lymphocytes displayed a mild sensitivity to TSA
(Figures 7a and b). EC50 values for XPA- and BLM-mutants were
Table 1. Cell lines used in this study.
Cell Type Mutation/Name Pathway or Description Origin
Chicken DT40 Wild-type Evans et al. 2010
Chicken DT40 XPA Nucleotide Excision Repair Evans et al. 2010
Chicken DT40 SHPRH DNA Post-replication Repair This study
Chicken DT40 BLM DNA Replication and Repair Evans et al. 2010
Chicken DT40 FANCC Interstrand crosslink Repair Evans et al. 2010
Chicken DT40 KU70/RAD54 Non-homologous End Joining/Homologous Recombination Evans et al. 2010
Chicken DT40 POLb Base Excision Repair Evans et al. 2010
Chicken DT40 REV3 Translesion DNA Synthesis Evans et al. 2010
Chicken DT40 FEN1 Base Excision Repair, Nucleotide Excision Repair, DNA ReplicationEvans et al. 2010
Chicken DT40 UBC13 DNA Post-replication Repair Evans et al. 2010
Chicken DT40 ATM Cell Cycle Checkpoint Evans et al. 2010
Human Lymphoblast Wild-type Candotti et al. 1997
Human Lymphoblast BLM DNA Replication and Repair Coriell
Human Lymphoblast XPA Nucleotide Excision Repair Coriell
Mouse Embryonic Fibroblast Wild-type Krijger et al. 2011
Mouse Embryonic Fibroblast SHPRH DNA Post-replication Repair Krijger et al. 2011
Human Embryonic Kidney HEK293T ATCC
Human Embryonic Kidney HEK293T ELG1-LUC Fox et al. 2012
Human Cervical Adenocarcinoma HeLa ATCC
Human Cervical Adenocarcinoma HeLa IHN20.22 Non-homologous End Joining Assay Cell Line This study
Human Cervical Adenocarcinoma HeLa IHN20.41 Non-homologous End Joining Assay Cell Line This study
Human Cervical Adenocarcinoma HeLa iHO4.5GFP Homologous Recombination Assay Cell Line This study
Human Colorectal Cancer HCT116 ATCC
Human Colorectal Cancer HCT116 FANCM Interstrand Crosslink Repair Wang et al. 2013
Human Colorectal Cancer HCT116 LIG4 Non-homologous End Joining Fattah et al. 2010
Oh et al. 2013
Human Ductal Carcinoma BRCA1 Corrected Yu et al. 2006
Human Ductal Carcinoma BRCA1 Homologous Recombination Yu et al. 2006
Human Osteosarcoma U2OS DR-GFP Homologous Recombination Assay Cell Line Xia et al. 2006
Human Osteosarcoma U2OS EJ2-GFP Alternative End Joining Assay Cell Line Gunn et al. 2012
Human Retinal Pigmented Epithelium RPE ATCC
doi:10.1371/journal.pone.0087203.t001
Table 2. EC50 values for isogenic chicken DT40 B lymphocyte
cell lines following 48 hour treatment with TSA and SAHA.
EC50
TSA nM SAHA mM
Wild-type 8.1 0.54
ATM 6.4 0.53
POLb 4.4 0.36
UBC13 4.1 0.82
KU70/RAD54 3.7 0.25
SHPRH 3.7 0.21
FEN1 3.2 0.82
XPA 1.9 0.18
FANCC 1.8 0.63
REV3 1.4 0.41
BLM 0.7 0.08
doi:10.1371/journal.pone.0087203.t002
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significantly different than wild-type (p= 0.009 and p= 0.02,
respectively). Although the EC50 values for SAHA treated XPA-
and BLM-mutants were not significantly different, there was a
clear sensitivity of the mutants at lower survival percentages
(Figures 7a and b). XPA- and BLM-mutants were both more
sensitive to MMS compared to wild-type (Figure S1b). This result
was similar to that observed in BRCA1-deficient cells (Figure 6a)
with the sensitivity differences between wild-type and mutant
reduced compared to what was observed in DT40 cells. SHPRH-
null MEFs did not show any sensitivity to either TSA or SAHA
when compared to wild-type MEFs (Figure 7c) and likewise, we
did not observe any difference in viability between FANCM-
deficient HCT116 cells compared to the control (Figure 7d)
following treatment with TSA or SAHA. As expected FANCM-null
cells were highly sensitive to treatment with MMS (Figure S1c).
We concluded that there are slight differences in the sensitivity of
avian and mammalian cells to HDACi therapeutics, but reaction
to HDACi treatment also varies widely between human tumors
[47] and the differences we observed might not be species specific.
Collectively, however, our data also indicate that TSA and SAHA
can be used to enhance the killing of cancer cells defective in
specific DNA repair pathways including those dependent on
BRCA1 or Rad51 (HDR), XPA (NER), or BLM.
The fact that NHEJ repair events are significantly enhanced by
HDACi strategies suggests that an error prone pathway of break
repair may contribute to toxicity by this class of drugs. In fact, it
has been shown that high doses of TSA induce aneuploidy in
lymphoblasts [48]. In marked contrast, the HDR pathway may
reconcile HDACi induced genotoxicity and provide a mechanism
that promotes survival of those cells that have this pathway intact.
The potential for HDACi drugs to target cells with HDR defects
and stimulate NHEJ events is significant. Our findings predict that
combining epigenetic drugs with traditional genotoxic therapies
represents a rational strategy to target cancer cells, which
frequently display HDR repair defects. In addition, activation of
NHEJ, which is a prominent, error prone path in human cells, also
contributes to the cytotoxic activity of HDACi in cancer cells.
Future studies will be required to fully understand the contribution
of NHEJ and HDR in directing tumor cell death by epigenetic
agents; however, we have powerful genetic and cell based
Figure 3. The effect of HDACis on SCE and HR Frequency. (A) RPE cells were treated with 0.2 mM TSA for 48 hr. Representative images of
metaphase spreads with arrows indicating SCEs (Magnification: 1006). (Inset) Magnification of the boxed region. (B) The graph represents the
average number of SCEs per cell 6 SD following treatment. Non-significance was determined using a two-tailed t-test. (C) Schematic of DR-GFP HR
frequency assay. (D) U2OS DR-GFP cells were transfected with pCGA-I-SCEI and then treated with 0.25 mM TSA for 48 hr. The graph represents the
average HR frequency 6 SD following treatment determined by FACS analysis. Non-significance was determined using a two-tailed t-test. (E)
Schematic of twin reporter DR-GFP HR assay. (F) HeLa iHO4.5GFP cells were pulsed for 24 hr with Dox, washed and chased in the presence of the
indicated amounts of TSA. The percentage of GFP-positive cells was determined by FACS analysis. The graph represents the average percent GFP 6
SD. The difference between +Dox/2TSA and +Dox/+TSA not significant and was determined using a two-tailed t-test.
doi:10.1371/journal.pone.0087203.g003
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reporting tools to enhance our understanding of each repair
pathway.
Materials and Methods
Chicken RAD5 (human SHPRH homolog) Cloning and
Gene Targeting Vectors
Two RAD5 disruption constructs, RAD5-puro and RAD-bsr,
were generated from genomic PCR products combined with
puromycin and blasticidin selection marker cassettes. Genomic
DNA sequences were amplified using SalI primer 59-TATAA-
GTCGA- CAGGTTGGAATCTACCTTCTGGAAGCAGG-39
and BamHI primer 59-TATAAGGATCCTAGA- TTTTCAC-
TCCATCCAGAGTAATGACC-39 (for the left arm of the KO
construct); and NotI primer 59-TATAAGCGGCCGCTTTGC-
TACAACACTTATTTGTTGCAACAGG-39 and BamHI primer
59-TATAAGGATCCGAAATAGACGGCTTCTCAAAAGAA-
CGCTGG39 (for the right arm primer of the KO construct).
Amplified PCR products were cloned into pBluescript II K. The
BamHI site was used to clone marker gene cassettes. 0.4 kb of
fragment from the genomic DNA amplified using the primers 59-
CAAAAAGATGACAGTCGTTCAAATCTAAATC- TGGG-39
and 59-CTTTAGAGCTTGACCCTCTCCAGG-39 was used as a
probe for Southern blot analysis.
Human FANCM and LIGIV Targeting
The mutants were generated in the HCT116 cell background.
The construction and phenotypes of LIGIV-null cells [43,44] and
FANCM-null cells [46] have been described.
Cell Culture
Isogenic DT40 cell lines [30], each defective in a different DNA
repair pathway (Table 1), were cultured in RPMI (Life Technol-
ogies) supplemented with 10% fetal bovine serum (FBS, Hyclone),
1% chicken serum (Life Technologies), 50 mM 2-mercaptoethanol
(Sigma), 1 mM L-glutamine (Life Technologies) and 1% penicillin-
streptomycin (Life Technologies). BLM- and XPA-defective lym-
phocytes (Coriell) were cultured in RPMI supplemented with 15%
FBS and 2 mM L-glutamine. Wild-type human lymphocytes [49]
were cultured in RPMI supplemented with 10% FBS, 1 mM L-
glutamine, 1 mM sodium pyruvate (Life Technologies), 1% non-
essential amino acids (Life Technologies), 50 mM 2-mercaptoeth-
anol and 50 mg/ml gentamycin sulfate (Life Technologies). Wild-
type and SHPRH mouse embryonic fibroblasts (MEFs) [50], RPE
(ATCC), HEK293T (human embryonic kidney) (ATCC), HeLa
Figure 4. The effect of HDACi on NHEJ. (A) Representative images of RPE nuclei (blue) with p-53BP1 foci (green) after a 24 hr treatment with
2 mM HU or 1 hr treatment with either 0.5 mM TSA or 32 mM SAHA. (B) The percentage of RPE cells containing the indicated number of p-53BP1 foci
following treatment as described in A was determined from at least 145 cells per treatment. (C) Schematic of NHEJ assay. HeLa IHN20.22 cells were
pulsed for 24 hr with Dox, washed and chased in the presence of the indicated amounts of TSA (D) or SAHA (E) for 3 days. The graphs represent the
average percent GFP 6 SD. Significance between +Dox/2TSA or SAHA and +Dox/+TSA or SAHA was calculated using a two-tailed t-test. The
percentage of GFP-positive cells was determined by FACS analysis.
doi:10.1371/journal.pone.0087203.g004
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(human cervical adenocarcinoma) (ATCC), HCT116 (human
colorectal cancer cell) (ATCC), U2OS EJ2-GFP [40], isogenic
HCT116 FANCM- [43,46] and LIG4- [43,44] null cells, HCC1937
cells complimented with a BRCA1 cDNA and HCC1937 [45] were
cultured in DMEM with Glutamax (Life Technologies) supple-
mented with 10% FBS and 1% penicillin- streptomycin. U2OS
DR-GFP [34,51] cells were cultured in McCoys modified 5A (Life
Technologies) supplemented with 10% FBS, 2 mM L-glutamine
and 1% penicillin-streptomycin. All cell lines were maintained in a
humidified environment of 5% CO2 and 95% air at 37uC.
Figure 5. Viability of NHEJ deficient cells after treatment with HDACis. The indicated cells were treated for 48 hr with 0 to 1.5 mM TSA, 0 to
100 mM SAHA or 0 to 118 mM MMS. Viability was determined using CellTiter-Glo. The data represent the average of 3 independent experiments 6
SD. (A) Hela cells after 24 hr transfection with either non-targeting siRNA or siRNA against KU80. (B) HCT116 LIG4-null or wild-type HCT116 cells.
(C) HCC1937 cells, lacking a functional BRCA1 gene, or HC1937 cells complimented by BRCA1 cDNA expression (wild-type).
doi:10.1371/journal.pone.0087203.g005
Figure 6. Viability of HDR deficient cells after treatment with HDACis. The indicated cells were treated for 48 hr with 0 to 1.5 mM TSA, 0 to
100 mM SAHA or 0 to 118 mM MMS. Viability was determined using CellTiter-Glo. The data represent the average of 3 independent experiments 6
SD. (A) HCC1937 cells, lacking a functional BRCA1 gene, or HC1937 cells complimented by BRCA1 cDNA expression (wild-type). EC50 differences
between wild-type and BRCA1 after treatment with TSA and SAHA were significant at p= 0.0009 and p= 0.02 respectively. EC50 differences between
wild-type and BRCA1 after MMS treatment were not significant p= 0.07. (B) Hela cells after 2624 hr transfection with either non-targeting siRNA or
siRNA against RAD51. EC50 differences between siNT and siRAD51 after treatment with TSA and SAHA were significant at p,0.0001 and p= 0.03
respectively. EC50 differences between siNT and siRAD51 after MMS treatment were not significant p = 0.07.
doi:10.1371/journal.pone.0087203.g006
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Luciferase Assay
HEK293T ELG1-LUC cells [25] were plated at a density of
10,000 cells per well in a 96-well white, assay plate (Costar). 24 hr
after seeding, cells were treated with 0.75 mM TSA or 50 mM
SAHA and then incubated for an additional 48 hr. Either One-
Glo luciferase reagent (Promega) to quantify luciferase activity or
Cell-Titre Glo to quantify cell viability was added to each well.
Luminescence intensity was measured using a Fluoroskan Ascent
Luminometer (Thermo Scientific). Luciferase levels were normal-
ized to cell viability.
Protein Analysis
HEK293T cells were grown in 10-cm tissue-culture plates to
,90% confluence and treated with 0.75 mM TSA, or DMSO
(negative control) for 24 hr. To obtain total lysate, the cells were
resuspended in lysis buffer [50 mM Tris, pH 7.5, 150 mM NaCl,
1% Nonidet P-40, 5 mM EDTA, protease inhibitors (Roche)] and
lysed on ice for 30 min. Chromatin-bound fractions were isolated
as described [52]. Proteins in the total lysate or the chromatin-
bound fraction were separated by SDS-PAGE using a 4–15% tris-
glycine gel (Bio-Rad) and transferred to a polyvinylidene difluoride
membrane. Proteins in the membrane were detected by the ECL
Western Blotting Detection System (GE Healthcare). HRP-
conjugated anti-PCNA was purchased from Santa Cruz Biotech-
nology. Rabbit antiphospho-RPA32 (S4/S8), and rabbit antipho-
spho-CHK1 (S317) antibodies were purchased from Bethyl
Laboratories. HRP-conjugated anti–b-tubulin antibody was pur-
chased from Abcam. Rabbit antihistone H3 antibody was
purchased from Upstate. Mouse antiphospho-histone H2AX
(S140, 3F2) antibody was purchased from GeneTex.
Pulsed-Field Gel Electrophoresis
HEK293T cells were treated with 100 uM TSA for 24 hours
and then Pulsed-field gel electrophoresis was performed as
described [25].
siRNA Knockdown of KU80 or RAD51
HeLa cells were transfected once with ON-TARGETplus
NON-targeting siRNA or siRNA targeting KU80 (Dharmacon)
or twice with siRNA targeting RAD51 (Dharmacon) using
Lipofectamine RNAi Max (Life Technologies). 24 hr post-
transfection, cells were treated with TSA (final concentration =
0 mM to 0.04 mM, Sigma) or SAHA (final concentration = 0 mM
to 3.125 mM, Cayman Chemical Company). 48 hr following
treatment, cell viability was determined using Cell Titer-Glo
(Promega) according to the manufacturer’s protocol. Viability was
quantified on a Fluoroskan Ascent Luminometer (Thermo
Scientific). Dose-response curves were generated using GraphPad
Prism. Protein levels were visualized using antibodies against
KU80 or RAD51 using whole cell extract prepared 72 hr after
transfection.
Figure 7. Effect of HDACi on the viability of mammalian cell lines. (A) BLM and (B) XPA human lymphocytes were treated with 0 to 1.5 mM
TSA or 0 to 100 mM SAHA for 48 hours. (C) SHPRH MEFs were treated with 0 to 1.5 mM TSA or 0 to 100 mM SAHA for 48 hours. (D) FANCM human
colorectal cancer cells were treated with 0 to 1.5 mM TSA or 0 to 100 mM SAHA for 48 hr. Viability was determined using CellTiter-Glo. The data
represent the average of 3 independent experiments 6 SD.
doi:10.1371/journal.pone.0087203.g007
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Viability Assays
All cells were cultured in 96-well white, assay plates (Costar).
DT40 cells were plated at a density of 1,000 cells per well. TSA
(final concentration = 0 mM to 0.04 mM, Sigma) or SAHA (final
concentration = 0 mM to 3.125 mM, Cayman Chemical Com-
pany) were added immediately after plating and cells were treated
for 48 hr. Human lymphoblasts were plated at a density of 20,000
cells per well. TSA (final concentration = 0 mM to 1.5 mM) or
SAHA (final concentration = 0 mM to 100 mM) were added
immediately after plating and cells were treated for 48 hr. MEFs
and fibroblasts were plated at a density of 5,000 cells per well. TSA
(final concentration = 0 mM to 1.5 mM) or SAHA (final
concentration = 0 mM to 100 mM) were added 24 hr after
plating and cells were treated for 48 hr. Following treatment, cell
viability was determined using Cell Titer-Glo (Promega) according
to the manufacturer’s protocol. Viability was quantified on a
Fluoroskan Ascent Luminometer (Thermo Scientific). Dose-
response curves were generated using GraphPad Prism.
Sister Chromatid Exchange (SCE) Assay
SCE was carried out as described [25]. Briefly, RPE cells were
treated with 0.2 mM TSA for 48 hr. Cells were washed with PBS
and then cultured in the presence 5 mg/ml BrdU for an additional
48 hours. Colcemid (0.05 mg) was added 3 hr prior to preparation
of metaphase spreads. Metaphase spreads on slides were prepared
by standard hypotonic treatment and fixation with methanol and
glacial acetic acid and incubated at 45uC for 18 hr before staining
with 2 mg/ml Hoechst 33258 in 2x SSC solution. The slides,
mounted with Sorensen’s phosphate buffer pH 7.0, were then
treated by UV light for 30 min and subsequently incubated at
65uC for 1 hr in 2x SSC. Chromosomes on slides were stained
with 4% Giemsa in Sorenson’s buffer pH 6.8 for 30 min and
monitored under microscope. Images of 50 metaphase spreads for
each cell line were captured from 2 independent experiments.
Immunofluorescence and Microscopy
56104 RPE cells were plated in each well of a 4-well chamber
slide (Nunc). 24 hr after plating, cells were treated for an
additional 24 hr with 2 mM HU or 1 hr with either 0.5 mM
TSA or 32 mM SAHA. Following treatment, slides were washed
with PBS then fixed with 4% paraformaldehyde/0.2% Triton X-
100 in PBS for 20 min. After a brief wash with PBS, slides were
permeabilized with 0.5% NP40 in PBS for 10 min and then
washed with 0.5% BSA/0.175% Tween-20 in PBS. Slides were
blocked for 1 hr in 1% donkey serum/2% BSA in PBS and then
incubated in rabbit antiphospho-53BP1-Ser1778 (Cell Signaling)
diluted 1:1000 in 3% BSA in PBS for 2 hr. After extensive washes
with 0.5% BSA/0.175% Tween-20 in PBS, slides were incubated
for 1 hr in Alexa-Fluor 488-conjugated goat anti-rabbit IgG
secondary antibody (Invitrogen) diluted 1:250 in 3% BSA in PBS.
Following washes in 0.5% BSA/0.175% Tween-20 in PBS, slides
were mounted with ProLong Gold Antifade Reagent with DAPI
(Life Technologies). Wide-field images were collected using a
Personal DeltaVision system (Applied Precision Inc., Issaquah,
WA, USA) mounted on an inverted Olympus IX71 microscope
with an oil immersion UPlanSApo 1006/1.40 objective lens. All
images were acquired using a CoolSNAP ES2 camera with 161
binning. Excitation filters 390/18 and 490/20 with corresponding
emission filters 435/48 and 528/38 were used to collect the DAPI
and Alexa-Fluor 488. All images were collected using the same
settings and all were deconvolved using an iterative constrained
method with 10 cycles, medium noise filtering in SoftWoRx
version 4.0.0. At least 145 cells were imaged from each treatment.
Recombination Reporter Assays
A U2OS cell line stably transfected with a single copy of an
intact DR-GFP reporter gene (gift from Dr. M. Jasin at the
Memorial Sloan-Kettering Institute) was used to measure the
HDR frequency [34,51]. A single DSB was introduced by
expressing the I-SceI endonuclease. Cells were treated with
0.25 mM TSA at 24 hr after transfection. After a 48 hr treatment,
cells were analyzed on a BDFACSCalibur with a 15 mW 488 nm
argon laser. GFP emission was detected with a 530/30 band-pass
filter and DsRed was detected with a 670LP filter. Data was
analyzed using FlowJo. The HDR frequency was determined by
the number of cells expressing GFP divided by the number of cells
expressing DsRed (as an indicator for transfection). Experiments
were repeated at least 3 times, and the average values are reported.
The Hela cell line iHO4.5GFP was used to measure the HDR
frequency. This cell line contains the DR-GFP reporter twin
cassettes (GFP-I, GFP-II) that are mutated and GFP minus.
Adjacent to the Cassette I, a unique I-SceI site was engineered and
the I-SceI gene introduced and placed under control of the Tet-on
promoter. Cells were either continuously exposed to doxycycline
(Dox) for 7 days, (new Dox added each day with medium change)
or pulsed with Dox for 24 hr and then washed and chased in Dox-
free medium for 7 days. HDR frequency was measured by FACS
analysis and reported as the percentage of GFP cells. The percent
GFP readout reveals the HDR frequency, based on Q-PCR
analyses, as shown previously [23].
Non-Homologous End Joining Reporter Assays
Two different clones of NHEJ reporter cells were constructed
and tested (IHN20.22 and IHN20.41 with similar results using
other clones, not shown). The NHEJ based reporter is based on
the construct from Mao et al. [39] and consists of a single GFP
cassette disrupted by an internal adenoviral exon and a Neomycin
selectable marker. The cassette also includes the CMV promoter;
however, due to the exon insertion, the cells are GFP minus.
Flanking the adenoviral exon are twin I-Sce1 sites that were placed
in an inverted orientation. Digestion with the homing endonucle-
ase I-Sce1, creates a DS DNA break with incompatible ends,
which are repaired by NHEJ. To create an inducible I-SceI
system, a stably transfected HeLa cell lines were made containing
a single integrated copy of the NHEJ (GFP) cassette. The construct
was validated by sequencing and qPCR to confirm copy number.
Two lentiviruses (pLV-TetO-HA-Sce1 and rtTA) were used to co-
infect this stable line. A number of clones were screened to identify
a single copy GFP cassette line that was induced by doxycycline
addition in a Tet-on format and two clones were selected for this
study. Following induction of I-SceI by addition of doxycycline,
DS DNA breaks are produced that flank the adenoviral exon. The
breaks can only be repaired by the NHEJ pathway (not HDR) and
in some repair products WT GFP is produced [53,54]. The
percent GFP was determined by FACS analysis as previously
described [22,23]. For this analysis, 26105 IHN20.22 or
IHN20.41 cells were plated in 35 mm dishes, plus or minus Dox
(or DMSO negative controls). Cells were pulsed with 0.5 ug
Doxycycline/mL for 24 hours to induce a detectable and
synchronous wave of NHEJ repair. At this time, TSA at the
indicated concentrations was added and the GFP measured as a
time course over 3 days by FACS analysis. Induction of I-SceI
gene expression was not affected by HDACi treatment, using this
approach. NHEJ was also analyzed using a complementary
approach with a U2OS cell line carrying an End Joining (EJ-5)
reporter in genome [40]. To measure NHEJ, 16105 U2OS EJ2-
GFP cells were plated in each well of a 6-well plate, and
transfected the next day with 3 mg of I-SceI expression vector
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(pCGA-I-SCE) and 10 ml of Lipofectamine LTX (Life Technol-
ogies) in culture medium without antibiotics. 24 hr after transfec-
tion, cells were treated with either DMSO as a negative control, or
with 100 nM TSA. NHEJ frequencies were measured by FACS
analysis (48 hr post-treatment) to reveal the total percent GFP.
siRNA knockdown was performed one time 24 hours prior to
transfection of I-SceI with ON-TARGETplus NON-targeting
siRNA, siRNA targeting KU80 (Dharmacon) or siRNA targeting
53BP1 (Dharmacon) using Lipofectamine RNAi Max (Life
Technologies). Protein levels were visualized using antibodies
against KU80 or 53BP1 using whole cell extract prepared 72 hr
after transfection.
Statistical Analyses
The Graphpad Prism 5 (Graphpad PrismH) software package
was used to perform statistical analyses.
Densitometry Analyses
AlphaView SA (Cell Biosciences) software was used to perform
densitometry analyses.
Supporting Information
Figure S1 (A) HeLa iHO4.5GFP cells were pulsed for 24 hr
with Dox, washed and then chased in the presence of the indicated
amounts of SAHA. The graph represents the average percent GFP
6 SD. The difference between +Dox/2SAHA and +Dox/
+SAHA not significant and was determined using a two-tailed t-
test. (B) BLM and XPA human lymphocytes were treated with 0 to
118 mM MMS for 48 hr. Viability was determined using
CellTiter-Glo. (C) FANCM human colorectal cancer cells were
treated with 0 to 118 mM MMS for 48 hr. Viability was
determined using CellTiter-Glo. (D) 72 hr after transfection with
either non-targeting siRNA or siRNA against KU86, protein levels
were visualized using antibodies against KU86. Relative densi-
tometry is shown on right. (E) 72 hr after transfection with either
non-targeting siRNA or siRNA against RAD51, protein levels
were visualized using antibodies against RAD51. Relative
densitometry is shown on right.
(TIF)
Figure S2 (A) HeLa IHN20.41 cells were pulsed for 24 hr with
Dox, washed and chased in the presence of the indicated amounts
of SAHA for 3 days. The percentage of GFP-positive cells was
determined by FACS analysis. The graph represents the average
percent GFP 6 SD. Significance between +Dox/2SAHA and
+Dox/+SAHA was calculated using a two-tailed t-test. (B) U2OS
EJ2-GFP cells were transfected with pCGA-I-SCEI and then
treated with 100 nM TSA for 48 hr. The graph represents the
average NHEJ frequency 6 SD following treatment determined
by FACS analysis. The difference between non-treated and TSA
treated was not significant and was determined using a one-tailed
t-test. (C) U2OS EJ2-GFP cells were transfected with non-
targeting siRNA or siRNA targeting KU80 or 53BP1. 24 hr after
knockdown, the cells were transfected with pCGA-I-SCEI and
then treated 24 hr later with 100 nM TSA for 48 hr. The graph
represents the average NHEJ frequency 6 SD following treatment
determined by FACS analysis. The difference between non-
targeting and KU80 knockdown was significant and was
determined using a two-tailed t-test. The difference between
non-targeting and 53BP1 knockdown was not significant and was
determined using a two-tailed t-test. (D) 72 hr after transfection
with either non-targeting siRNA, siRNA against Ku80 or siRNA
against 53BP1, protein levels were visualized using antibodies
against indicated proteins. Relative densitometry is shown on
right. (E) Analysis of SAHA induced NHEJ in iHN20.22 cells. The
NHEJ reporter cells were not treated with Doxycycline in order to
assess direct genotoxicity and NHEJ recovery in the absence of
directed DSBs at the I-Sce1 site. Cells were incubated for 24 hr. in
the indicted concentrations of SAHA and percent GFP was
determined by FACS 6 SD.
(TIF)
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